Earnings
EBIT and EBITDA
Following the severe impact of the coronavirus pandemic in the prior-year period when earnings before interest and tax (EBIT) totaled just €272.8 million, EBIT in the first nine months of 2021 reached €623.9 million, reflecting the widespread recovery of the market. EBIT included budgeted negative effects from purchase price allocations totaling €63.1 million (Q1–Q3 2020: €66.4 million). There were also non-recurring items amounting to a total expense of €4.1 million in the reporting period. The prior-year figure, an expense of €24.6 million, mainly included adverse effects on earnings from the capacity and structural program as well as an impairment charge on an equity investment. EBIT adjusted for non-recurring items and purchase price allocation effects (adjusted EBIT) amounted to €691.1 million in the first nine months of the year (Q1–Q3 2020: €363.8 million). The adjusted EBIT margin improved to 9.2 percent (Q1–Q3 2020: 6.1 percent).
in € million |
Q3 |
Q3 |
Q1 – Q3 |
in % of revenue |
Q1 – Q3 |
in % of revenue |
---|---|---|---|---|---|---|
EBITDA |
209.1 |
135.2 |
623.9 |
8.3% |
272.8 |
4.5% |
Adjustment by functional costs: |
|
|
|
|
|
|
+ Cost of sales |
9.5 |
14.8 |
28.4 |
0.4% |
35.1 |
0.6% |
+ Selling expenses and administrative expenses |
13.0 |
11.5 |
42.5 |
0.6% |
47.2 |
0.8% |
+ Research and development costs |
0.0 |
0.0 |
0.1 |
0.0% |
0.2 |
0.0% |
+ Other costs |
–2.8 |
–2.4 |
–3.9 |
–0.1% |
8.6 |
0.1% |
Adjusted EBITDA |
228.9 |
159.1 |
691.1 |
9.2% |
363.8 |
6.1% |
adjusted for non-recurring items |
–1.4 |
2.2 |
4.1 |
0.1% |
24.6 |
0.4% |
adjusted for PPA items |
21.2 |
21.6 |
63.1 |
0.8% |
66.4 |
1.1% |
Earnings before interest, tax, depreciation, and amortization (EBITDA) rose to €1,317.6 million (Q1–Q3 2020: €962.1 million). Adjusted EBITDA increased to €1,321.4 million (Q1–Q3 2020: €986.7 million), giving an adjusted EBITDA margin of 17.5 percent (Q1–Q3 2020: 16.4 percent).
in € million |
Q3 |
Q3 |
Q1 – Q3 |
in % of revenue |
Q1 – Q3 |
in % of revenue |
---|---|---|---|---|---|---|
EBITDA |
443.7 |
365.0 |
1,317.6 |
17.5% |
962.1 |
16.0% |
Adjustment by functional costs: |
|
|
|
|
|
|
+ Cost of sales |
0.0 |
4.8 |
0.0 |
0.0% |
4.8 |
0.1% |
+ Selling expenses and administrative expenses |
1.4 |
–0.2 |
8.0 |
0.1% |
11.2 |
0.2% |
+ Research and development costs |
0.0 |
0.0 |
0.0 |
0.0% |
0.0 |
0.0% |
+ Other costs |
–3.2 |
–2.4 |
–4.2 |
–0.1% |
8.6 |
0.1% |
Adjusted EBITDA |
441.9 |
367.3 |
1,321.4 |
17.5% |
986.7 |
16.4% |
adjusted for non-recurring items |
–1.9 |
2.2 |
3.8 |
0.0% |
24.6 |
0.4% |
adjusted for PPA items |
0.0 |
0.0 |
0.0 |
0.0% |
0.0 |
0.0% |
EBITDA for the long-term leasing business, which is derived from internal reporting and assumes a minimum rate of return on the capital employed, amounted to €248.8 million in the reporting period (Q1–Q3 2020: €248.6 million).